NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace (NPCE) posted quarterly Preferred Stock Liabilities of $141.4 million for Q1 2021, up 92.23% year-over-year from $73.6 million in Q1 2020, and little changed quarter-over-quarter from $141.4 million in Q4 2020.
NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
NeuroPace's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $141.4 million for Q1 2021.
- In Q1 2021, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million; the TTM figure through Mar 2021 stood at $141.4 million (up 92.23% YoY), while the FY2020 annual figure was $141.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2021 stood at $141.4 million, roughly flat from $141.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $141.4 million in Q3 2020, with the low at $73.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | - |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | - |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | - |
| 10 | NeuroPace | 469.45 Mn | 417.75 Mn | 18.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 141.42 Mn |
| Dec 31, 2020 | 141.42 Mn |
| Sep 30, 2020 | 141.42 Mn |
| Jun 30, 2020 | 73.45 Mn |
| Mar 31, 2020 | 73.57 Mn |